Multi-functionalized Nano-conjugate for combating multidrug resistant breast Cancer via starvation-assisted

Jing Zhang1, Lijia Liang1, Zhiyuan Li2

  • 1State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, People's Republic of China.

Insights

A novel nano-conjugate targets cancer cells, depleting glucose and oxygen to enhance chemotherapy effectiveness against multi-drug resistant (MDR) cancers. This strategy shows significant potential for overcoming drug resistance and improving patient outcomes.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Multi-drug resistance (MDR) is a major obstacle in cancer treatment, leading to therapy failure.
  • Developing strategies to overcome MDR and sensitize resistant cancer cells to chemotherapy remains a significant challenge.

Purpose of the Study:

  • To design a multi-functionalized nano-conjugate for starvation therapy to sensitize cancer cells to chemotherapy.
  • To investigate the potential of this nano-conjugate in overcoming multi-drug resistance in cancer.

Main Methods:

  • A nano-conjugate (AuNP-PEG-RGD) was synthesized, incorporating glucose oxidase (GOx) and a cancer-targeting peptide (RGD).
  • The nano-conjugate was used to create a glucose-depleted, hypoxic microenvironment with hydrogen peroxide (H2O2) generation.
  • The therapeutic efficacy of the nano-conjugate in combination with doxorubicin (Dox) was evaluated on breast cancer cells.

Main Results:

  • The nano-conjugate specifically targeted cancer cells and induced apoptosis by depleting glucose and oxygen, generating H2O2.
  • A combination of low-dose Dox (0.2 μg/mL) and the nano-conjugate (22.5 pM) effectively killed 80% of cancer cells, demonstrating synergistic effects (combination index < 1).
  • The strategy showed potential in sensitizing multi-drug resistant cancer cells to previously ineffective drugs.

Conclusions:

  • The developed nano-conjugate effectively sensitizes cancer cells to chemotherapy by disrupting their metabolic pathways.
  • This approach offers a promising strategy for overcoming multi-drug resistance and treating resistant cancers.
  • The findings have potential applications in reducing the incidence of MDR development and treating drug-resistant malignancies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K